Celyad Announces Closing of Global Offering

May 22, 2018, 10:02 pm

≫ Next: Trump factor leaves Macron scrambling ahead of Russia trip

≪ Previous: SeaBird Exploration: 2D survey in North West Europe

$

0

0

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies, today announced the closing of a global offering of 2,070,000 ordinary shares to purchasers in the United States, Europe and certain countries outside the United States and Europe, comprised of 568,500 ordinary shares in the form of American Depositary Shares (ADSs) Reported by Business Wire 3 hours ago.

---

Trump factor leaves Macron scrambling ahead of Russia trip

May 22, 2018, 11:07 pm

≫ Next: Intertrust N.V. share repurchase periodic update (14 - 18 May 2018)

≪ Previous: Celyad Announces Closing of Global Offering

$

0

0

By John Irish and Michel Rose PARIS (Reuters) - Emmanuel Macron heads to St Petersburg on Thursday seeking to win concessions from Vladimir Putin, but with Europe-U.S. Reported by Firstpost 2 hours ago.

Intertrust N.V. share repurchase periodic update (14 - 18 May 2018)

May 22, 2018, 10:22 pm

≫ Next: Vapiano records significant increase in sales and profitability in Q1 2018

≪ Previous: Trump factor leaves Macron scrambling ahead of Russia trip

$

0

0

*Amsterdam, the Netherlands - 23 May 2018 - *Intertrust N.V. ("Intertrust" or "Company") [Euronext: INTER], a leading global provider of high-value trust, corporate and fund services, today announces that it has repurchased 105,860 ordinary Intertrust shares at an average price of EUR 16.2494 per share in the period from 14 May 2018 up to and including 18 May 2018.

The aggregate consideration for this repurchase was EUR 1.72 million. This repurchase was made as part of the Company's share repurchase programme, which was announced on 13 November 2017.

The total number of shares repurchased under this programme up to and including 18 May 2018 is 2,943,602 shares for a total aggregate consideration of EUR 46.92 million.

Approximately 850,000 shares will be used for employee stock ownership and incentive plans vesting in 2018 and 2019, with the remainder of the repurchased shares to be cancelled (after approval by the general meeting of shareholders). Further details on the share repurchase transactions can be found on the Company's website.

This press release contains information which is to be made publicly available under the Market Abuse Regulation (EU) No 596/2014.

*For further information *
Intertrust N.V.                                                              marieke.palstra@intertrustgroup.com
Marieke Palstra                                                             Tel: +31 20 577 1157
Director of Investor Relations and Corporate Communications

*About Intertrust*
Intertrust is a leading global provider of high-value trust, corporate and fund services, with more than 2,500 employees located throughout a network of 39 offices in 28 jurisdictions across Europe, the Americas, Asia and the Middle-East. The Company delivers high-quality, tailored services to its clients with a view to building long-term relationships. Intertrust's business services offering is comprised of corporate services, fund services, capital market services, and private wealth services. Intertrust has leading market positions in selected key geographic markets of its industry, including the Netherlands, Luxembourg, Jersey, and the Cayman Islands. Intertrust works with global law firms and accountancy firms, multi-national corporations, financial institutions, fund managers, high net worth individuals and family offices.

*Attachment*

· intertrust-nv-share-buyback-update-wk20-23052018.pdf Reported by GlobeNewswire 3 hours ago.

Vapiano records significant increase in sales and profitability in Q1 2018

May 22, 2018, 10:42 pm

≫ Next: Fast Europe Open: UK inflation, eurozone manufacturing PMI

≪ Previous: Intertrust N.V. share repurchase periodic update (14 - 18 May 2018)

$

0

0

DGAP-News: VAPIANO SE / Key word(s): Quarterly / Interim Statement

23.05.2018 / 07:30
The issuer is solely responsible for the content of this announcement.
--------------------

*Vapiano records significant increase in sales and profitability in Q1 2018*

· Group sales up by 14.5% to EUR 86.3 million in Q1 2018
· Like-for-like sales growth of 0.1%, encouraging like-for-like growth in Germany of 2.2%
· Significant increase in adjusted EBITDA of 32.2% to EUR 9.3 million, adjusted EBITDA margin rose by 1.4 percentage points from 9.3% to 10.7%
· Strong growth in reported EBITDA of 92.3% to EUR 6.9 million, result for the period improved by 41.4% to EUR -4.1 million
· Three restaurant openings in the first quarter and considerable roll-out of the take away and home delivery business to 103 restaurants and thus 50% of the restaurant network
· Management Board confirms guidance for 2018Cologne, May 23, 2018* *- Vapiano SE (ISIN: DE000A0WMNK9, ticker symbol: VAO) has continued its successful growth in the first three months of 2018. Group sales (corporate and consolidated joint venture restaurants) rose to EUR 86.3 million, an increase of 14.5% compared to the same period in the previous year (EUR 75.4 million). The increase in sales resulted primarily from the positive performance of the Rest of Europe segment, which grew by 26.9%, mainly driven by the numerous new restaurant openings in 2017. The Germany segment also performed encouragingly, with sales growth of around 7.7%. Sales in the Rest of World segment (including the USA and China) declined slightly by EUR 0.3 million to EUR 3.8 million, due to the remodelling of the Chinese pilot restaurant.

Like-for-like Group sales were slightly higher year-on-year with 0.1%. The Germany segment performed positively with like-for-like growth of 2.2%. Due to a modest first quarter in Sweden and the Netherlands, like-for-like sales performance was -1.8% for the Rest of Europe segment; for the Rest of World segment it was -3.6%.

The adjusted result before interest, taxes, depreciation and amortization (adjusted EBITDA^[1]), Vapiano's most important key performance indicator of the operating earnings performance as a growth company, rose in the first three months of the financial year by a pleasing 32.2% to EUR 9.3 million. The adjusted EBITDA margin improved accordingly by 1.4 percentage points, from 9.3% to 10.7%. Reported EBITDA also improved significantly by 92.3% to EUR 6.9 million, and the reported EBITDA margin rose by 3.2 percentage points to 8.0%. The positive EBITDA performance is primarily due to the new restaurants opened in 2017, the implemented operational improvement concept OPEX, and the positive performance of the take away and home delivery business.

Jochen Halfmann, CEO of Vapiano SE, said: "We are satisfied with the operating performance in the first quarter. Although like-for-like growth in the first three months was more modest than in the previous year, especially in Sweden and the Netherlands, we expect an improvement during the rest of the year. The significant increase in our adjusted EBITDA of 32.2% and the almost doubling of our reported EBITDA is very pleasing. In addition to our digitalization measures, the continued consistent implementation of our operational excellence program OPEX contributed to this. We have also successfully continued our expansion with eight restaurant openings to date in 2018. Seven more will follow by the end of the first half. In addition, we have now equipped 103 locations, or around 50% of our restaurant network, with the attractive take away and home delivery services. In the next months, we will resolutely expand our international expansion as well as the digital share of our business, while at the same time further increase our company's profitability."

The depreciation and amortization of EUR 10.3 million (Q1 2017: EUR 8.9 million) in the first quarter of 2018 was largely attributable by the scheduled depreciation on property, plant and equipment and was due to the capital expenditure made in the course of the growth and expansion strategy. The result for the period for the first three months of 2018, improved significantly year-on-year to EUR -4.1 million (Q1 2017: EUR -7.0 million). The adjusted result for the period - based on the adjusted EBITDA and corrected for depreciation, amortization and tax effects due to franchise rights gained through company acquisitions - was slightly positive at EUR 0.5 million in the first quarter of 2018, compared to EUR -1.4 million in the prior-year period.

As of the end of March 2018, equity stood at EUR 126.6 million (equity ratio: 35.1%). Operating cash flow before interest and taxes amounted EUR 2.8 million in the three-month period (Q1 2017: EUR 7.0 million).

In the three-month reporting period, Vapiano opened three restaurants across the globe. By the date of this release, five more restaurants had been opened, bringing Vapiano's international presence to 209 restaurants in 33 countries.

The Management Board of Vapiano SE confirmed its guidance for the 2018 financial year and its estimates for sales of between EUR 390 million and EUR 420 million and like-for-like growth of between 1% and 3%. Adjusted EBITDA is expected to increase to between EUR 48 million and EUR 54 million.

The quarterly financial report and the presentation for analysts and investors are available on the investor relations website (http://ir.vapiano.com) under the heading "Reports & Presentations".

___
[1] Adjusted for significant extraordinary effects for the IPO, up-front costs for restaurant openings and other one-time effects, e.g. due to currency fluctuations. The adjustments increase transparency, as the adjusted EBITDA best reflects the operating performance of the company and increases comparability of the figures over time.
*VAPIANO SE - Key performance indicators (in EUR million)*

  *Q1 2018* *Q1 2017* *Change*
*System sales*

(Corporate, joint venture and franchise restaurants) 129.9 118.1 10.0%
*Group sales*

(Corporate and consolidated joint venture restaurants) 86.3 75.4 14.5%
*Like-for-like Group sales * 0.1% 4.3% -
*Average sales per guest (in EUR)* 11.6 11.3 2.2%
*Adjusted EBITDA* 9.3 7.0 32.2%
*Adjusted EBITDA margin* 10.7% 9.3% -
*Reported EBITDA* 6.9 3.6 92.3%
*Reported EBITDA margin* 8.0% 4.8% -
*Adjusted result for the period** 0.5 -1.4 135.6%
*Adjusted earnings per share (in EUR)* 0.02 -0.07 130.2%
*Reported result for the period* -4.1 -7.0 41.4%
*Reported earnings per share (in EUR)* -0.14 -0.34 58.8%
*Cash flow from operating activities before taxes and interest* 2.8** 7.0 -59.7%
*Investment in tangible and intangible assets * -14.4 -16.2 11.1%
*Investment for acquisitions* 0.0 -0.7 100.0%
*Cash flow from investing activities* -14.4 -16.9 14.8%
*Cash flow from financing activities* 13.9 11.4 21.9%

* Result for the period corrected to take account of EBITDA adjustments plus correction for depreciation, amortization and tax effects from company acquisitions. The term of depreciation for fixed assets was adjusted to 10 years, as for comparable companies

** Operating cash flow in Q1 2018 is impacted by reclassification of cash in transit (EUR 3.2 million).
 

  *3/31/2018* *12/31/2017* *Change*
*Balance sheet total* 361.0 350.3 3.1%
*Equity* 126.6 131.1 -3.4%
*Equity ratio* 35.1% 37.4% -
*Net debt* 128.2 116.2 10.3%
*Net debt/adjusted EBITDA (in years)* 3.10 2.99 3.7%

       
  *3/31/2018* *12/31/2017* *Change*
*Number of restaurants* 206 205 1*

* Net change (incl. closing two restaurants)
*About Vapiano*

In 2002, Italian lifestyle brand Vapiano created a new category in system gastronomy with its innovative "fresh casual dining" concept combining elements from "fast casual" and "casual dining". The restaurant concept is based on quality, uncompromisingly fresh ingredients, and transparency. Pasta, pizza dough, sauces, dressings and desserts are handmade each day in every Vapiano. The dishes are prepared in front of the guests "à la minute" and "customized" to the guests' requirements. The recipe for success also includes the cosmopolitan ambiance. Long oak tables invite communication, a fully grown olive tree and a cozy bar and lounge area characterize the feel-good atmosphere found in every Vapiano. Vapiano also represents autonomy and individuality, so guests can choose between different "guest journeys". Guests decide whether they will order their food from the Vapianisti, at the terminal or via the VAPIANO app, and whether they will pay via chip card or app. The company has also successfully been offering take away and delivery services in a growing number of restaurants so guests can enjoy Vapiano "anytime, anyplace, anywhere". The successful concept has quickly spread from Hamburg all over the world. As of March 31, 2018, there were 206 restaurants in 33 countries on five continents in the Vapiano network. Vapiano shares (ISIN: DE000A0WMNK9) have been traded on the Prime Standard segment of the Frankfurt Stock Exchange since June 27, 2017. Further information can be found at ir.vapiano.com.*Investor Relations Contact: *

Dr. Andrea Rolvering
Cellphone: +49 151 5445 9750
Tel: +49 221 67001 301
Email: a.rolvering@vapiano.eu

*Financial and Business press:*
Dariusch Manssuri, IR.on AG
Cellphone: +49 173 566 2776
Tel: +49 221 9140 975
Email: dariusch.manssuri@ir-on.com
--------------------

23.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: VAPIANO SE
Im Zollhafen 2-4
50678 Cologne
Germany
Phone: +49 (0) 221 67001-0
Fax: +49 (0) 221 67001-205
E-mail: info@vapiano.eu
Internet: www.vapiano.com
ISIN: DE000A0WMNK9
WKN: A0WMNK
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange
 
End of News DGAP News Service Reported by EQS Group 2 hours ago.

Fast Europe Open: UK inflation, eurozone manufacturing PMI

May 22, 2018, 10:36 pm

≫ Next: Man United still the most valuable club in Europe

≪ Previous: Vapiano records significant increase in sales and profitability in Q1 2018

$

0

0

Reported by FT.com 3 hours ago.

Man United still the most valuable club in Europe

May 22, 2018, 11:24 pm

≫ Next: Verona Pharma Files Shelf Registration Statement with SEC

≪ Previous: Fast Europe Open: UK inflation, eurozone manufacturing PMI

$

0

0

Manchester United remain the most valuable club in Europe according to the latest study of leading teams. Reported by RTE.ie 2 hours ago.

Verona Pharma Files Shelf Registration Statement with SEC

May 22, 2018, 11:01 pm

≫ Next: Elanix Biotechnologies AG: Elanix Biotechnologies AG strengthens its sales network by signing an Agreement with MedBioSante, Moscow-Based Distributor for GYNrepair(R)

≪ Previous: Man United still the most valuable club in Europe

$

0

0

Shareholders’ Circular and Notice of General Meeting

LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs, announces that it has filed a $200 million shelf registration statement on Form F-3 (the “Shelf Registration Statement”) with the Securities and Exchange Commission (the "SEC").  Once declared effective by the SEC, the Shelf Registration Statement will permit the Company to issue or sell, from time to time over the next three years, up to $200 million in aggregate value of its ordinary shares of £0.05 each (“Ordinary Shares”), American Depositary Shares, warrants or units (together the “Securities”).The Company may use the Shelf Registration Statement on an as-needed basis to raise equity capital for general corporate purposes, which may include the funding of the Phase 3 clinical development and commercialization of the Company’s product candidate, RPL554, for the treatment of chronic obstructive pulmonary disease, as well as the funding of additional development of RPL554 for the treatment cystic fibrosis and other indications. The Company has no immediate plans to issue or sell Securities pursuant to the Shelf Registration Statement, which is intended to provide financial flexibility to access additional capital in a competitive and expeditious manner when market conditions are appropriate.

The filing of a shelf registration statement is a common practice by Nasdaq-listed companies and may be effected following the first anniversary of a company listing on Nasdaq provided certain requirements are met, including timely regulatory reporting. Once declared effective by the SEC, the Shelf Registration Statement will be in effect for a period of three years, or such earlier time that the $200 million worth of Securities registered under the Shelf Registration Statement have been issued or sold. Any offers, solicitations of offers to buy, or sales of, the Securities will only be made once the Shelf Registration Statement and any prospectus supplement relating to it has been declared effective by the SEC.

The Company also announces that it will today publish and post to shareholders an explanatory circular (the “Circular”) containing a notice of general meeting (the “General Meeting”) at which resolutions will be proposed to seek authority in advance to allot shares or rights to subscribe for, or convert any security into shares, up to an aggregate nominal amount equivalent to 52,508,700 Ordinary Shares and permit the disapplication of statutory pre-emption rights in respect of the allotment of any such securities, such authorities to be valid for the three years following the General Meeting.

As stated above, the Company has no immediate plans to use such authority to raise equity capital but the Directors consider it to be in the best interests of the Company and its shareholders as a whole for the Company to have the flexibility to access additional capital when market conditions are appropriate in a competitive and expeditious manner and accordingly unanimously recommend that the shareholders vote in favour of the resolutions to be proposed at the General Meeting.

The Circular incorporates a notice convening the General Meeting to be held at the offices of Latham & Watkins (London) LLP, 99 Bishopsgate, London, EC2M 3XF, United Kingdom on June 26, 2018 at 4:00 p.m. An electronic copy of the Circular will be available on the Company's website at: http://www.veronapharma.com.

*About Verona Pharma plc*

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

*Forward Looking Statements*

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the use of proceeds for any funds raised under the Shelf Registration Statement, the Shelf Registration Statement providing financial flexibility to access additional capital in a competitive and expeditious manner when market conditions are appropriate, and the period of effectiveness of the Shelf Registration Statement.

All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of RPL554, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of RPL554, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with RPL554, which could adversely affect our ability to develop or commercialize RPL554; potential delays in enrolling patients, which could adversely affect our research and development efforts; we may not be successful in developing RPL554 for multiple indications; our ability to obtain approval for and commercialize RPL554 in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; the loss of any key personnel and our ability to recruit replacement personnel, material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize RPL554; and lawsuits related to patents covering RPL554 and the potential for our patents to be found invalid or unenforceable.

These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on February 27, 2018, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

*THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 *

*For further information, please contact:*

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
   
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison  
   
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
   
ICR, Inc. (US Media and Investor enquiries)  
James Heins Tel: +1 203-682-8251

  James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282

  Stephanie.Carrington@icrinc.com
    Reported by GlobeNewswire 2 hours ago.

Elanix Biotechnologies AG: Elanix Biotechnologies AG strengthens its sales network by signing an Agreement with MedBioSante, Moscow-Based Distributor for GYNrepair(R)

May 22, 2018, 11:14 pm

≫ Next: Global Lubricants Market Will Reach USD 146.3 Billion by 2024: Zion Market Research

≪ Previous: Verona Pharma Files Shelf Registration Statement with SEC

$

0

0

DGAP-News: Elanix Biotechnologies AG / Key word(s): Contract/Agreement

23.05.2018 / 08:00
The issuer is solely responsible for the content of this announcement.
--------------------

 

*PRESS RELEASE *

*Elanix Biotechnologies AG strengthens its sales network by signing an Agreement with MedBioSante, Moscow-Based Distributor for GYNrepair(R)*

*Collaboration with MedBioSante Extends Sales of Advanced Skin Care Products to Russian Market*

*Berlin, Germany, 23 May, 2018* -- Elanix Biotechnologies AG (FRA: ELN), a developer of tissue regeneration products for chronic and acute wound care and advanced skin care products for dermatological and gynaecological applications, has signed a distribution agreement with MedBioSante to make its progenitor cell-based creams available in Russia. Through this partnership, Elanix will initially sell its products via a gynaecologist prescription network in Moscow before extending its reach through digital sales channels to other Russian cities and the CIS states from next year.

GYNrepair(R) cream, which is developed and marketed by Elanix's wholly-owned subsidiary Repair A, contains a proprietary Cell Free Protein Complex (CFPC(R)), including various proteins, such as collagen and fibronectin, and is perfume-free. It is specifically designed for use on the genital external mucosa to soothe the feeling of discomfort, twinges and dryness.

"This collaboration with a Moscow-based specialist distributor is a part of our strategy to increase availability of our advanced skin care products across Europe," said Tomas Svoboda, CEO of Elanix Biotechnologies. "We look forward to making our GYNrepair cream more widely available as we expand on this partnership and extend our reach across Russia and the CIS states."

"We are enthusiastic about this new partnership with Elanix Biotechnologies and proud to bring a technology-driven product in the field of gynaecological cosmetics to the Russian market to help meet increasing demand," said Maia Karlovna Filippova-Kokeladze, CEO of MedBioSante. "We are confident this will represent a long-term partnership and greater collaboration in the future."

*####*

*Elanix *develops and commercializes tissue regeneration products for chronic and acute wound care as well as advanced skin care for dermatological and gynecological applications. Additionally, Elanix provides services in cell therapy and related technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix has registered headquarters in Berlin, Germany, with offices in Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com.

Follow us on Twitter @elanix_biotech

*MedBioSante*, headquartered in Moscow (Russia) and with a branch in Geneva (Switzerland), provides outsourcing services throughout Russia, CIS and Eastern European countries for pharmaceutical and cosmetic companies. MedBioSante operates in the area of distribution, sales and the promotion of pharmaceutical products, foodstuffs and cosmetics and provides services in the field of certification and registration of medical devices and pharmaceutical products throughout the Russian Federation, CIS and Eastern European countries.

*Contacts:*
Elanix Biotechnologies AG
Magdalena Onyszkiewicz
Tel: +41 78 667 3650
investor.relations@elanix-bt.com

*Disclaimer / Forward-looking statements: *
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
--------------------

23.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: Elanix Biotechnologies AG
Kurfürstendamm 32
10719 Berlin
Germany
Phone: +41 22 363 66 40
Fax: +41 22 363 66 41
E-mail: info@elanix-bt.com
Internet: www.elanixbiotechnologies.com
ISIN: DE000A0WMJQ4
WKN: A0WMJQ
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf
 
End of News DGAP News Service Reported by EQS Group 2 hours ago.

---

Global Lubricants Market Will Reach USD 146.3 Billion by 2024: Zion Market Research

May 22, 2018, 11:21 pm

≫ Next: Freedom of expression in Europe: Who draws the line?

≪ Previous: Elanix Biotechnologies AG: Elanix Biotechnologies AG strengthens its sales network by signing an Agreement with MedBioSante, Moscow-Based Distributor for GYNrepair(R)

$

0

0

According to the report, global lubricants market was valued at around USD 117.4 Billion in 2017, and is expected to reach approximately USD 146.3 Billion by 2024, growing at a CAGR of slightly above 3.0% between 2017 and 2024.

New York, NY, May 23, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Lubricants Market by Product (Greases, Bio-based, Synthetic and Mineral oil) by Application (Industrial, Automotive, Marine and Aerospace) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024’’*. According to the report, global lubricants market was valued at around USD 117.4 Billion in 2017 and is expected to reach approximately USD 146.3 Billion by 2024, growing at a CAGR of slightly above 3.0% between 2017 and 2024.

Lubrication controls wear and friction between moving surfaces with an introduction of friction reducing film. It can be a plastic, solid or fluid substance. Various substances can be used as a lubricant to lubricate surfaces; grease and oil are most common amongst these. Grease consists of a thickening agent and oil, oil actually lubricates whereas a thickening agent is used for consistency. Oils can be mineral/ vegetable based synthetic or can be a combination of these.

*Browse through 67 Tables & 22 Figures spread over 130 Pages and in-depth TOC on "Global Lubricants Market Size & Share Report 2017: Industry Type, Applications, and Forecast, 2024”.*

*Request Free sample Report of Global Lubricants Market Report @ *https://www.zionmarketresearch.com/sample/lubricants-market

The flourishing demand of general, military and commercial aviation has given a positive outlook to the aviation industry, thus increasing usage of lubricants for their fleet maintenance. Boosting air traffic worldwide, especially in developing countries has expanded airlines commercial fleet size. Further, the upsurge in global economy along with rising disposable income has led to passenger’s inclination towards air travel. In 2017, global air traffic increased by 4.5% along with the economic growth of above 2.5% as compared to previous year. Commercial fleet expansion has driven many associated industries, resulting in escalating demand of lubricants during the forecast period. 

Increasing need to harvest various crop coupled with rising demand of agricultural products will flourish industrial machinery market over the forecast timeframe. These machines require lubrication at regular time intervals to function efficiently and effectively. Further, growing R&D in various sectors such as automation of operations, data management, steering systems will positively influence industrial machinery growth. Encouraging regulatory norms pertaining to tax benefits in infrastructure ventures will fuel construction activities in South Korea, Japan, and India. This would increase demand for construction machinery such as earthmoving equipment offering potential opportunities to machinery in the sector.

*Download Free Report Brochure: *https://www.zionmarketresearch.com/requestbrochure/lubricants-market

Based on product, lubricants market is classified as greases, bio-based, synthetic and mineral oil. Mineral oil would contribute majorly in the market share owing to its wide application in the chemical and technical industry to enhance the manufacturing process. Various applications involving the use of lubricants are industrial, automotive, marine and aerospace. Aerospace industry will grow substantially due to increasing fleet traffic and maintenance operations of aircraft.

North America is projected to witness a substantial demand of lubricants during the forecast period. The region is a major contributor in overall aircraft strength accounting for above 9,300 aircraft in 2016. Higher commercial aircraft usage along with their increasing age is responsible for product penetration. Aerospace composites demand in the region is projected to increase at above 7% till 2024 with a market size of over USD 1 billion in 2016. This defines the potential of the aviation industry in the region. Regular innovations in the product coupled with fuel-efficient aircraft engines demand will propel the industry growth. Further, ever-increasing defense budget in the U.S. along with safety-related regulations mandates the lubrication of military and commercial aircraft. Thus, promising positive outlook of the product in the region during the forecast period.

Browse the full *"Lubricants Market by Product (Greases, Bio-based, Synthetic and Mineral oil) by Application (Industrial, Automotive, Marine and Aerospace) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024"* report at https://www.zionmarketresearch.com/report/lubricants-market  

Europe will account for a significant share in global lubricants market owing to its growing industrial applications. The region will register a growth of nearly 4.5% in industrial machinery market till 2024. Stringent regulations pertaining to many aspects such as exhaust emission limitations, safety concerns and quiet operations of machines will lead to frequent lubrication of machinery. Further, strong automobile growth of the European countries such as Germany will contribute in the regional size. Germany is the hub for automobile giants such as Opel, Audi, BMW, Mercedes-Benz, and Volkswagen. Especially, Western Europe has witnessed abundant demand for vehicles along with stringent regulations imposed by government authority for driver’s safety. This would ensure proper lubrication of vehicle parts and engine along with the whole vehicle body.

In 2017, Asia Pacific accounted for above 60% in global marine engines production. Positive outlook of the marine industry in the region will make it a significant contributor in global lubricants market. Numerous manufacturers coupled with an investment in R&D ventures for marine engine designs will strengthen the product outlook. Increasing marine trade in South East Asia, especially across Indonesia and China will further support the business growth. China marine lubricants industry is propelled by its shipbuilding industry coupled with the government subsidy to build and scrap ships. The subsidy policy has been implemented from the end of 2017. To avail the benefits of the policy Chinese operators have to scrap their old ships and place an order to replace the vessel, boosting the lubrication consumption.

*Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/lubricants-market

Brazil marine lubricant industry would grow at above 4% till 2024. The growth is attributed to its international seaborne trade. The country would be setting up “hidrobras”, an entity to take care of Brazil’s inland waterways ports and terminals. Brazil government is working on maintenance of waterways along with restructuring marine ports to cover underutilized waterways. This would lead to additional vessels demand, increasing the product consumption.

Global lubricants producers are adopting aggressive strategies to expand their footprints in the market. The industry is dominated by few major companies and new entrants find it difficult to set themselves in the global market. Giant manufacturers in the competition include Royal Dutch Shell, Total S.A., Chevron Corporation, Exxon Mobil Corporation, and BP P.L.C. These players account for more than 40% of the market share.

*Request customized copy of report @ *https://www.zionmarketresearch.com/custom/2938

*The report segments global Lubricants market as follows:*

*Lubricants Market: Product Segment Analysis*

· Greases
· Bio-based
· Synthetic
· Mineral oil

*Lubricants Market: Application Segment Analysis*

· Industrial
· Automotive
· Marine
· Aerospace

*Lubricants Market: Regional Segment Analysis*

· North America

· The U.S.

· Europe

· UK
· France
· Germany

· Asia Pacific

· China
· Japan
· India

· Latin America

· Brazil

· The Middle East and Africa

*Related Reports:*

· *Isostearic Acid Market:* https://www.zionmarketresearch.com/report/isostearic-acid-market
· *Conductive Polymers Market:* https://www.zionmarketresearch.com/report/conductive-polymers-market
· *Friction Modifiers Market:* https://www.zionmarketresearch.com/report/friction-modifiers-organic-inorganic-market
· *Chemical Surface Treatment Market:* https://www.zionmarketresearch.com/report/chemical-surface-treatment-market
· *Rigid Transparent Plastics Market: *https://www.zionmarketresearch.com/report/rigid-transparent-plastics-market

*About Us:*

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research

*Blog:* http://industrydailynews.com | http://www.e-marketresearch.com | http://marketglobalnews.com  | http://theindustrytoday.com  | https://detroitnews24.com  | http://thebookofkindle.com

CONTACT:
Contact Us:

Joel John

244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com Reported by GlobeNewswire 2 hours ago.

Freedom of expression in Europe: Who draws the line?

May 22, 2018, 11:38 pm

≫ Next: A Nintendo 64 console reissue might be on the way

≪ Previous: Global Lubricants Market Will Reach USD 146.3 Billion by 2024: Zion Market Research

$

0

0

Hate speech laws are spreading in Europe as EU governments and international organisations try to find measures to defuse conflicts. Reported by EurActiv 2 hours ago.

A Nintendo 64 console reissue might be on the way

May 22, 2018, 11:48 pm

≫ Next: Bellevue Asset Management AG: Bellevue launches dedicated digital health fund

≪ Previous: Freedom of expression in Europe: Who draws the line?

$

0

0

Over the past couple of years, Nintendo made its beloved 8-bit and 16-bit consoles, the NES and SNES, available in modern avatars with preloaded games for fans of the originals. Now, Nintendo Life reports that a similar effort with the Nintendo 64 might be underway. That’s from a Japanese trademark application for the N64 that Nintendo has reportedly filed, based on JapaneseNintendo.com’s post. It’s worth noting that the company previously applied for a similar trademark in Europe last year, as well as one for the Game Boy, and nothing materialized then. But with just weeks to go before the E3…

This story continues at The Next Web

Or just read more coverage about: Nintendo Reported by The Next Web 1 hour ago.

Bellevue Asset Management AG: Bellevue launches dedicated digital health fund

May 22, 2018, 11:47 pm

≫ Next: Top EU Official Warns Israel 'Not to Disparage Europe' – Reports

≪ Previous: A Nintendo 64 console reissue might be on the way

$

0

0

EQS Group-News: Bellevue Asset Management AG / Key word(s): Product Launch

23.05.2018 / 08:34
--------------------

Media Release of May 23, 2018*Bellevue launches dedicated digital health fund**A raft of new technologies is changing the way healthcare systems function and creating new growth opportunities in the process. Bellevue Asset Management first began to invest in this groundbreaking market in April 2016 via its BB HealthTech open-end certificate. The successful strategy behind this proprietary investment vehicle managed by portfolio managers Stefan Blum and Marcel Fritsch is now being replicated in a Luxemburg-based investment fund - the BB Adamant Digital Health (Lux) Fund (ISIN B-CHF LU1811047833). *

The digital revolution has touched people's lives in many ways. Digitalization has also been embraced by the healthcare system. New technologies that fall under the "Digital Health" label are being rolled out across the sector and the benefits are plain to see. Digitalization is creating value in the form of more effective treatment options or direly needed efficiency gains and cost savings, for example. Thanks to disruptive technologies such as sensors, connectivity and cloud computing, many new or improved products and services are now being introduced to the marketplace with positive effects on treatment outcomes and on the cost side. Examples of Digital Health breakthroughs are telemedicine, robotic surgical systems and continuous glucose monitoring devices, to name just a few.

*Not your typical tech fund *

Digital health is a business that is subject to stricter regulations than the typical tech industry: Safety and clinical benefit must be verified in rigorous, painstaking clinical trials. Such requirements pose entry barriers to potential new rivals, make the related technology risk more predictable and give the fund a distinctive profile. The BB Adamant Digital Health (Lux) Fund (ISIN B-CHF LU1811047833) offers investors access to a global portfolio of rapidly growing technology stocks that are benefiting from the healthcare sector's attractive fundamentals, which include an aging population and the spread of lifestyle-related diseases. The value of the stocks in the fund's portfolio in the near to mid-term future will be shaped by top-line growth, the achievement of well-defined milestones and M&A activity.

*Successful strategy will be maintained*

Portfolio managers Stefan Blum and Marcel Fritsch will use the same investment strategy that has already proven so successful with the BB HealthTech certificate. This open-end certificate was issued in April 2016 and has since achieved an average annual return of about 30% on volatility of about 15%. "Venture capitalists have invested about USD 24 bn in 1 700 private digital health firms during the past 7 years, so we expect many attractive companies to go public in the coming years. Which is another argument to invest in the sector," remarks portfolio manager Stefan Blum. Attention will continue to focus on fast-growing small and mid-cap companies in North America, Europe and Asia. "In our fundamental bottom-up process, we will select 30 to 50 of the most attractive stocks out of a universe of 220 to 250 companies," Marcel Fritsch explains. "The key criteria for inclusion in the fund are sales growth and gross profit margins, a solid balance sheet and the quality of company management."

*25 years of healthcare expertise*

With the launch of this new investment fund, Bellevue continues to build its core competency as a healthcare sector investor. Bellevue already ranks among the largest independent healthcare investors in Europe. Twenty highly qualified healthcare investment experts manage a total of CHF 5.4 bn via various investment solutions.*For further information please contact:*

Bellevue Asset Management AG, Seestrasse 16 / P.O. Box, CH-8700 Küsnacht/Zurich
Tanja Chicherio, Tel. +41 44 267 67 09, tch@bellevue.ch
www.bellevue.ch

*Bellevue Asset Management*

Bellevue Asset Management and its sister company StarCapital based in Oberursel outside Frankfurt, Germany are part of Bellevue Group, an independent, Swiss financial group with a registered office in Zurich and a listing on the Swiss Exchange SIX. Bellevue was established in 1993 and has since become a leading investment boutique with a focus on healthcare, regional strategies, multi-asset solutions and global equity and bond funds. Assets under management amount to CHF 9.4 bn*Disclaimer: *This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information and data presented in this document are not to be considered as an offer or solicitation to buy, sell or subscribe to any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. No liability is assumed for its correctness and accuracy. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient and in particular tax treatment depends on individual circumstances and may be subject to change. This document is not to be relied upon in substitution for the exercise of independent judgment. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in the light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. The details and opinions contained in this document are provided without any guarantee or warranty and are for the recipient's personal use and information purpose only. Every investment involves risk, especially with regard to fluctuations in value and return, and investors' capital may be at risk. If the currency of a financial product is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Past performance is no indicator for the current or future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs have a negative impact on performance. This document does not reflect any risks related to investments into the mentioned securities and financial instruments. Financial transactions should only be undertaken after having carefully studied the current valid prospectus and are only valid on the basis of the latest version of the prospectus and available annual and semi-annual reports. As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied. The Bellevue Funds (Lux) SICAV is admitted for public offering and distribution in Switzerland. Representative agent in Switzerland: Acolin Fund Services AG, Affolternstrasse 56, CH-8050 Zürich and paying agent in Switzerland: Bank am Bellevue AG, Seestrasse 16, P.O. Box, CH-8700 Kusnacht. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria. Paying and information agent: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A-1010 Vienna. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany. Paying and information agent: Bank Julius Bär Europe AG, An der Welle 1, P.O. Box, D-60062 Frankfurt a. M. The Bellevue Funds (Lux) SICAV is recognised for public offering and distribution in the United Kingdom. Facilities agent: Global Funds Registration Limited, 1st Floor, 10 New Street, London EC2M 4TP.The Bellevue Funds (Lux) SICAV is registered with the CNMV under the number 938. Prospectus, Key Investor Information Document ("KIID"), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16, CH-8700 Kusnacht.

 

 

--------------------
Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=STBYMSLVVT
Document title: Media release --------------------

End of Corporate News -------------------- Reported by EQS Group 1 hour ago.

Top EU Official Warns Israel 'Not to Disparage Europe' – Reports

May 22, 2018, 11:54 pm

≫ Next: Yaya Toure wants sensational Manchester United move, Arsenal want Seri and EPL clubs battle it out with Bundesliga's best for German wonderkid

≪ Previous: Bellevue Asset Management AG: Bellevue launches dedicated digital health fund

$

0

0

Reported by RIA Nov. 1 hour ago.

Yaya Toure wants sensational Manchester United move, Arsenal want Seri and EPL clubs battle it out with Bundesliga's best for German wonderkid

May 23, 2018, 12:04 am

≫ Next: Financial Fitness Group Expands Morningstar Relationship to Launch New Financial Education Solution for Financial Services Institutions

≪ Previous: Top EU Official Warns Israel 'Not to Disparage Europe' – Reports

$

0

0

All the latest transfer news and rumours form across the EPL and Europe Reported by Plymouth Herald 1 hour ago.

Financial Fitness Group Expands Morningstar Relationship to Launch New Financial Education Solution for Financial Services Institutions

May 23, 2018, 12:05 am

≫ Next: In'Tech Medical enters into agreement to acquire Bradshaw Medical, industry leader in silicone overmolded solutions, ratchet and torque devices

≪ Previous: Yaya Toure wants sensational Manchester United move, Arsenal want Seri and EPL clubs battle it out with Bundesliga's best for German wonderkid

$

0

0

The new Morningstar® Investing Classroom™Deluxe offers financial services firms the opportunity to create engaged, confident and educated investors

SAN DIEGO (PRWEB) May 23, 2018

Precision Information, LLC., DBA Financial Fitness Group (FFG) (http://www.FinancialFitnessGroup.com), headquartered in San Diego, CA, which provides interactive financial education solutions for the financial services industry and Inc. 5000 companies across the nation, celebrates 20 years of providing financial education to the American workforce by launching a new financial education solution with Morningstar, Morningstar® Investing Classroom™ Deluxe, an educational tool with expanded topics and a gamification engine to help investors track the progress of their financial goals.

“It is exciting to see a simple but innovative idea that was hatched and then refined by a graduate student and later a faculty member at the UW-Madison grow to positively impact thousands of companies and millions of people,” said Joe Saari, Founder & Chairman of Financial Fitness Group. “Our work with Morningstar is helping us make a positive impact in empowering people to take control of their financial fitness.”

Over ten years ago, FFG and Morningstar worked together to launch the original Morningstar® Investing Classroom™, which helps savers improve their investing skills and consists of interactive online courses, quizzes, and learning modules, that are available on Morningstar.com and from financial services firms who license the content for their users.

Morningstar Investing Classroom Deluxe expands the Investing Classroom offering with more than 250 interactive courses including financial planning, stocks, bonds, mutual funds, exchange-traded funds, and more. The expanded product now boasts a mobile-friendly design to allow for anytime learning and a recommendation engine to help investors build a personalized financial action plan. Another new feature is the gamification engine, which allows investors to track progress within Investing Classroom Deluxe.

“Morningstar and FFG are working together to achieve a shared mission: help investors make informed decisions,” said Marc DeMoss, Morningstar’s head of research licensing and distribution. “FFG is a long-standing collaborator with Morningstar on improving financial wellness and increasing financial education for investors. We are excited to broaden our offering with the enhanced content and functionality we’re adding to Investing Classroom Deluxe.”

Financial Wellness in America
Since the 1970’s, the United States has shifted the burden of saving for retirement from the employer to the employee. Pensions are now a thing of the past, and employees have taken on the sole responsibility for their financial futures. 80% of the workforce is living paycheck to paycheck - with 46% of those employees stressing about finances at work at least 3 hours per week. FFG, was created to help empower the individual to become more profitable and suffer less daily stress. Their online education solutions were specifically developed to reduce the anxiety, lack of clarity or absence of financial planning that yields uncertainty related to money, including debt, medical bills, saving for retirement or children’s education. FFG impacts people’s lives by giving them the knowledge and information to confidently reach their financial goals.

###

About Precision Information, DBA Financial Fitness Group:
Financial Fitness Group (FFG) is an enterprise software company that developed multiple academically based financial e-learning platforms and actionable ecosystems designed to maximize employee engagement, personal financial knowledge, and predictive behavioral linkages. Since 1998 Financial Fitness Group has partnered with the country’s most forward-thinking financial institutions and workforce service providers to empower more than 2 million employees within more than 1,000 major U.S. corporations, universities and government agencies. Our cloud-based, independent and unbiased financial education and engagement platform, assesses and benchmarks participants overall financial fitness. Our company was founded in 1998 based on scientific research around how to improve the financial literacy of the citizens of the United States. That research continues to this day and is the driving force, along with our clients, to continuously meet the new challenges facing those with financial stress.

As part of the financial learning journey, the Financial Fitness Group developed the Financial Fitness SCORE™. This score allows participants to identify, benchmark, and positively change their financial aptitude, behavior, and confidence. Our exclusive, robust online content enables users to build up their Financial Fitness SCORE™ in a fun, engaging manner using a foundation of over 10,000 pieces of FINRA-reviewed content each user can select from. The platform is modular and easily adaptable to enterprise-level capacity offering solutions to meet each organization's unique needs. Our financial fitness platform has been developed to be turnkey so that it is simple to roll out and administer. Our platform can be configured to each client's needs and includes online and offline communication assets, a step-by-step best practice guide, and 1-million data points to cross check each user's progress and engagement through real-time analytics.

About Morningstar, Inc.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offers an extensive line of products and services for individual investors, financial advisors, asset managers, retirement plan providers and sponsors, and institutional investors in the private capital markets. Morningstar provides data and research insights on a wide range of investment offerings, including managed investment products, publicly listed companies, private capital markets, and real-time global market data. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $201 billion in assets under advisement and management as of March 31, 2018. The company has operations in 27 countries.

For additional information, images, and press materials, please contact Georgette Regan, georgette@financialfitnessgroup.com.

Financial Fitness Group Social Media:·     https://www.facebook.com/financialfitnessgroup/
·     https://twitter.com/FinancialFitGrp
·     https://plus.google.com/+FinancialFitnessGroup
·     https://www.youtube.com/channel/UC9fzUGn7vA3qLeW0P6EwejA

Morningstar Media Relations Contact:
Godhuli Gupta, +1 312 244-7577 or godhuli.gupta@morningstar.com Reported by PRWeb 1 hour ago.

---

In'Tech Medical enters into agreement to acquire Bradshaw Medical, industry leader in silicone overmolded solutions, ratchet and torque devices

May 23, 2018, 12:05 am

≫ Next: Imagination appoints PowerVR veteran to lead business unit

≪ Previous: Financial Fitness Group Expands Morningstar Relationship to Launch New Financial Education Solution for Financial Services Institutions

$

0

0

With the acquisition of Bradshaw Medical, In’Tech Medical re-enforces its position as the leading contract manufacturer for Orthopedics, providing end-to-end solutions to its customers worldwide.

MEMPHIS, Tenn. (PRWEB) May 23, 2018

In’Tech Medical SAS (http://www.intech-medical.com), the leading Contract Manufacturer of medical devices in Orthopedics, announced today that it has entered into a binding agreement to acquire world renowned instruments and silicone overmold company, Bradshaw Medical Inc. The transaction, supported by Eurazeo PME, has been approved by the Board of Directors of both organizations.

Based in Kenosha, Wisconsin, Bradshaw Medical is an innovation-driven company that has built a first-class reputation with a relentless focus on customer service.

With over 40 issued patents, Bradshaw’s engineering team has designed a broad portfolio of OEM instruments and provides the industry with highly-customizable silicone overmolded solutions.

"With the addition of Bradshaw Medical to the In’Tech family, we are re-enforcing our position as a leading Contract Manufacturer of surgical instruments in Orthopedics, as well as adding significant market penetration power,” said Laurent Pruvost, President of the In’Tech Medical Group. “Enhancing our offering with Bradshaw’s high-quality OEM instruments portfolio and its silicone overmolding expertise, provides the group with unparalleled capabilities and scale. Together we look forward to reshaping the orthopedic market, with game changing “smart” instruments.”

With over 800 employees and projected 2018 revenues of approximately $120 million, In’Tech Medical is now a premiere engineering powerhouse, capable of delivering manufacturing solutions anywhere, at any time, to the benefit of medical device organizations worldwide.

“Bradshaw Medical is excited to begin this next chapter in our company’s history,” said Guy Bradshaw, Founder & CEO. “We take great pride in providing the industry with the highest quality surgical instrumentation and customer service. Our tremendous growth and success over the past 12 years is a direct reflection of our dedicated employees. Forming an alliance with In’Tech Medical will allow us to take our brand global and provide the orthopedic industry with our combined ground-breaking technology.”

In’Tech and Bradshaw will be exhibiting jointly at OMTEC, in Chicago, June 12-14 and look forward to sharing with everyone the group’s vision of the instruments for tomorrow.

About In’Tech Medical (OMTEC booth #630)
Founded in France in 2000, In’Tech Medical is a global leading contract-manufacturer of surgical instruments, implants, as well as sterilization cases and trays. Powered by 650 dedicated employees across the USA, Europe and Asia-Pacific, the company is strategically positioned to deliver customized solutions to complex engineering and supply chain challenges. Driven by innovation, In’Tech continuously enhances its product & service offering to accelerate time-to-market for its customers worldwide.

Since July 2017, In’Tech Medical’s development strategy is supported by Eurazeo PME and Andera Partners (formerly Edmond de Rothschild Investment Partners) alongside its management team.

About Bradshaw Medical (OMTEC booth #226)
Founded in 2006, Bradshaw Medical Inc. is an industry leader in specialized design and development of OEM and spinal instrumentation. Bradshaw Medical has continually evolved over the past decade to meet the most demanding requirements of the orthopedic marketplace. Reported by PRWeb 1 hour ago.

Imagination appoints PowerVR veteran to lead business unit

May 23, 2018, 12:10 am

≫ Next: OpSec Partners with Blockpool to Develop Blockchain Security Applications

≪ Previous: In'Tech Medical enters into agreement to acquire Bradshaw Medical, industry leader in silicone overmolded solutions, ratchet and torque devices

$

0

0

EVP Nigel Leeder to drive expansion into new markets

LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- Imagination Technologies announces the appointment of Nigel Leeder as executive vice president of its PowerVR business unit. Previously, Leeder performed senior leadership roles for PowerVR for over a decade, guiding the evolution of PowerVR’s Graphics Processing Units (GPUs) and advances into AI technologies. Leeder is the first senior appointment by Imagination’s new CEO Dr. Leo Li since he joined the company in April 2018.Dr. Leo Li, CEO, Imagination Technologies says: “Since Imagination first began creating GPUs in the UK over 25 years ago, it has had a huge impact on the world – with over six billion PowerVR cores shipped. Nigel has been a driving force behind the success of PowerVR and so we are delighted to see him prosper and now lead the team. I’m sure his insight will enable us to deliver an even greater focus on customer success and alignment with their needs. PowerVR has been the first to many milestones – the first commercial tile based differed renderer, the first mobile 3D GPU, the first mobile HD video solution and now the first variable precision mobile AI accelerator. Under the expert leadership of Nigel, we will see many more firsts for PowerVR.”

Nigel Leeder says: “I’m proud and delighted to be leading PowerVR at such an exciting time for both the company and the PowerVR team. We have an aggressive plan to deliver ground-breaking performance and efficiency, and to expand into new and exciting markets. The combination of our GPU, compute and AI technologies puts Imagination in an enviable position of being able to fire up markets from mobile to consumer, automotive, autonomous systems and smart vision, and with exciting partnerships we have established in the USA, Europe and across Asia. We are confident this is the start of an exciting phase in technology development, driven from Imagination.”

Previously, Leeder led the customer engineering team which was responsible for delivering and supporting all Imagination technology deliverables to its customers and guiding its roadmap evolution based on those deep engagements. He has been intrinsic in delivering success for Imagination’s most important and influential customer engagements over the complete history of Imagination’s IP business.

*About Imagination Technologies
*Imagination is a global technology leader whose products touch the lives of billions of people across the globe. The company’s range of silicon IP (intellectual property) includes key processing blocks needed to create the SoCs (Systems on Chips) that power all mobile, consumer and embedded electronics. Its unique multimedia, vision & AI, and connectivity technologies enable its customers to get to market quickly with complete and differentiated SoC platforms. Imagination’s licensees include many of the world’s leading semiconductor manufacturers, innovative start-ups and OEMs/ODMs who are creating the world’s most iconic products. See: www.imgtec.com.

Follow Imagination on Twitter, YouTube, LinkedIn, RSS, Facebook and Blog.

Imagination, PowerVR and the Imagination Technologies logo are trademarks of Imagination Technologies Limited and/or its affiliated group companies in the United Kingdom and/or other countries. All other logos, products, trademarks and registered trademarks are the property of their respective owners.

*Imagination Technologies’ Press Contacts:
*David Harold - david.harold@imgtec.com  +44 (0)1923 260 511

Jo Ashford - jo.ashford@imgtec.com  +44 (0)1923 260 511 Reported by GlobeNewswire 1 hour ago.

OpSec Partners with Blockpool to Develop Blockchain Security Applications

May 23, 2018, 12:10 am

≫ Next: MARIMEKKO CORPORATION: MANAGERS' TRANSACTIONS

≪ Previous: Imagination appoints PowerVR veteran to lead business unit

$

0

0

LANCASTER, Pa., May 23, 2018 (GLOBE NEWSWIRE) -- OpSec Security, a leading global provider of anti-counterfeiting and brand protection solutions, has announced a partnership with Blockpool, a UK-based blockchain developer.  The relationship seeks to establish an integrated offer combining “chain-of-custody” with advanced digital product authentication solutions for global brand protection.With its first product release in 2009, Blockpool quickly established itself as an expert in leveraging blockchain technologies into real world offers. Blockpool’s Application Programming Interface (API) is more flexible and user-friendly than other, more rigidly structured market offers. Blockpool’s expertise leverages decades of tech, marketing and music industry experience. 

Founded over three decades ago, OpSec has established itself as a market leader working with thousands of the world’s leading brands, government agencies and security printers to provide comprehensive security solutions to combat growing counterfeiting business challenges.

“We’re in an age where counterfeiting exists in the everyday lives of consumers,” said Ben Stump, CTO of OpSec Security. “Adding blockchain technologies to our track/trace and consumer engagement platforms will provide an enhanced layer of security and confidence for both brands and consumers alike.”

OpSec will leverage its industry-leading product lifecycle platform, OpSec InSight™, to integrate with Blockpool’s “chain-of-custody” solutions. The result will empower brands to increase reporting precision and create new, unique consumer engagement opportunities utilizing advanced security tags and labels.

Kevin Bacon, Blockpool CEO, said, “Blockchain technologies can be leveraged to provide greater supply chain visibility and combat the distribution of counterfeit products, especially over the internet.  Brands want to ensure that their products are protected and reward their customers for loyalty.”

“Distributed Ledger Technology, and in particular blockchain, is already promising to heavily disrupt the way supply chains are controlled and vetted,” continued Ken Foster, Blockpool CTO.  “By partnering with OpSec, we can provide a perfect synergy of online and offline technologies.”

*About OpSec Security*

OpSec Security is the market leader in fighting counterfeits for brands, transaction cards and government documents and currency. OpSec delivers a comprehensive suite of end-to-end solutions, including advanced physical security technologies, supply chain track and trace services, and online and e-commerce monitoring and analysis for thousands of companies across industry sectors and 50 governments worldwide. OpSec is a wholly-owned division of OpSec Security Group Limited and operates manufacturing and software development facilities and laboratories in the USA, the UK, and Germany and has sales operations in the Americas, Europe, and Asia. For more information, please visit www.opsecsecurity.com. Follow OpSec on Twitter @OpSecSecurity, Facebook and LinkedIn.

*About Blockpool *

Blockpool, based in the UK, builds B2B blockchain solutions with a specialty in Delegated Proof of Stake (DPoS) and Platform as a Service (PaaS) software solutions. Creative use of the blockchain aimed at non-technical users has been a cornerstone of their development thus far.

The company is rooted in blockchain having launched Audiocoin (ADC) back in 2009. They had a successful funding round in 2016 and operate across multiple verticals.

In 2017, Blockpool partnered with the One Little Indian label to deliver blockchain based payment processing and creative rewards for Bjork’s latest album Utopia.  More recently, Blockpool announced a partnership with worldwide network of music studios and equipment retailers, Miloco Studios, creating a new paradigm for the music eco-system.

CONTACT: For further information, contact:
OpSec Security, Inc.                                                                                       
Branddy Spence
Director, Corporate Communications                                                                     
bspence@opsecsecurity.com                                                   
+1 410 917 8943 Reported by GlobeNewswire 1 hour ago.

MARIMEKKO CORPORATION: MANAGERS' TRANSACTIONS

May 23, 2018, 12:10 am

≫ Next: 10 things in tech you need to know today (FB)

≪ Previous: OpSec Partners with Blockpool to Develop Blockchain Security Applications

$

0

0

Marimekko Corporation, Managers’ Transactions, 23 May 2018 at 10.00 a.m.

____________________________________________

Person subject to the notification requirement
Name: Kari Härkönen
Position: Other senior manager
Issuer: Marimekko Oyj
LEI: 74370053IOY42B9YJ350

Notification type: INITIAL NOTIFICATION
Reference number: 74370053IOY42B9YJ350_20180523083338_4
____________________________________________

Transaction date: 2018-05-22
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009007660
Nature of the transaction: ACQUISITIONTransaction details
(1): Volume: 174 Unit price: 14.2 EUR
(2): Volume: 176 Unit price: 14.2 EUR

Aggregated transactions
(2): Volume: 350 Volume weighted average price: 14.2 EUR*
*

*
*

MARIMEKKO CORPORATIONReleased by: Corporate Communications, Piia Kumpulainen, tel. +358 9 758 7293

DISTRIBUTION:
Nasdaq Helsinki Ltd
Key mediaMarimekko is a Finnish design company renowned for its original prints and colours. The company’s product portfolio includes high-quality clothing, bags and accessories as well as home décor items ranging from textiles to tableware. When Marimekko was founded in 1951, its unparalleled printed fabrics gave it a strong and unique identity. Marimekko products are sold in about 40 countries. In 2017, brand sales of the products worldwide amounted to EUR 193 million and the company's net sales were EUR 102 million. Roughly 160 Marimekko stores serve customers around the globe. The key markets are Northern Europe, North America and the Asia-Pacific region. The Group employs about 450 people. The company’s share is quoted on Nasdaq Helsinki Ltd. www.marimekko.com Reported by GlobeNewswire 1 hour ago.

10 things in tech you need to know today (FB)

May 23, 2018, 12:12 am

≫ Next: CTS Eventim AG & Co. KGaA: CTS EVENTIM achieves significant revenue and earnings growth in first quarter of 2018

≪ Previous: MARIMEKKO CORPORATION: MANAGERS' TRANSACTIONS

$

0

0

Good morning! This is the tech news you need to know this Wednesday.

*1. Mark Zuckerberg largely managed to dodge awkward questions during his testimony to European lawmakers, thanks to the limited format of the hearing. *Zuckerberg mostly retrod old ground in his answers to questions about shadow profiles and the Cambridge Analytica scandal.

*2. A US civil liberties organisation has found that Amazon is marketing its powerful facial recognition tool to police.* The tool is already being used by one agency to check photographs of unidentified suspects against a database of mug shots from the county jail.  

*3. Facebook is expanding its efforts to fight revenge porn, asking users in the UK, Australia, the US, and Canada to upload any intimate images of themselves which they fear might be shared without their permission.* Those images would be shared with specially trained Facebook representatives and then be marked to prevent them being shared on Facebook, Instagram, or Facebook Messenger.

*4. Google's autocomplete feature on search reveals the names of victims in sexual assault cases, even though they are granted lifetime anonymity under UK law.* Google said it was investigating instances where victims' names had been revealed.

*5. Europe's top data protection official said it's likely Facebook has many more Cambridge Analytica-style scandals to come, thanks to its policy of allowing developers to build on its platform.* He also said it isn't clear if Facebook would have been fined for the scandal under upcoming European privacy rules.

*6. SoftBank is selling its entire stake in Indian ecommerce company Flipkart to Walmart, worth an estimated $4 billion.* The decision means Walmart is now the sole shareholder in Flipkart after it paid $16 billion for a 77% stake.

*7. Starbucks' mobile payment system is so popular that it's actually bigger than Apple's.* According to eMarketer statistics, 23.4 million US customers use Starbucks’ mobile payments compared with 22 million using Apple Pay.

*8. Tesla has poached a senior engineer from Snap, which has seen something of an exodus of top talent recently.* Stuart Bowers left his role as vice president of monetisation engineering at Snap to become vice president of engineering at Tesla. 

*9. HTC leaked details about its upcoming smartphone, the HTC U12 Plus, one day ahead of its expected launch.* An HTC test site showing details about the phone was taken down.

*10. Facebook's executive leadership is surprisingly loyal, according to an analysis by the website Recode.* Only one member of upper management, Mike Vernal, has left Facebook, while the average tenure of executives is almost ten years.

Join the conversation about this story »

NOW WATCH: How a tiny camera startup is taking on Amazon and Google Reported by Business Insider 59 minutes ago.